A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

NCT05415215 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

346

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Breast Cancer
Locally Advanced Breast Cancer
Inflammatory Breast Cancer

Interventions

DRUG: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
DRUG: Pertuzumab IV
DRUG: Trastuzumab IV
DRUG: Trastuzumab Emtansine
DRUG: Investigator's Choice of Chemotherapy
PROCEDURE: Surgery
RADIATION: Radiotherapy

Sponsor

Hoffmann-La Roche